Characteristics of patients receiving Alem/TBI/Cy (CLL3C trial)
Patient age, y/sex . | Binet stage . | Cytogenetics, VH status . | Stage, skin . | . | Onset, d . | GVHD/rash . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Histology . | . | Manifestation . | Treatment . | Outcome . | Complications and outcome . | MRD . | ||
| GVHD | ||||||||||||
| 64/M | B | 11q-, unmut | 3 | GVHD grade I | 92 | Maculopapular rash, conjunctivitis, sicca syndrome, wasting syndrome, diarrhea, duodenitis | Steroids, CSA, FK506 | Ongoing, 638 d+ | Cytopenia, pneumonia; patient died | Negative 439 d+ | ||
| 53/F | B | None, unmut | 1 | Acute GVHD | 43 | Maculopapular rash | Steroids, topical steroids | Ongoing, 867 d+ | CMV, herpes zoster | Negative 876 d+ | ||
| 51/F | B | None, unmut | 1 | GVHD grade I | 324 | Erythema, eczema, conjunctivitis, sicca syndrome, cholestasis | Steroids | Ongoing, 428 d+ | CLL transformation, allogeneic SCT | NA | ||
| 51/M | C | 13q-, unmut | 3 | — | 63 | Eczema, erythrodermia, conjunctivitis, sicca syndrome, cholestasis, diarrhea | Steroids | Resolved, 619 d | VZV, pneumonitis, Hashimoto thyroiditis | Negative 511 d+ | ||
| 34/M | C | None, unmut | 1 | — | 149 | Itching, dry and scalding skin, conjunctivitis, cholestasis | Topical steroids | Resolved, 399 d | Cytopenia, herpes zoster | Negative 511 d+ | ||
| 54/M | B | 13q-, mut | 3 | GVHD grade I | 68 | Maculopapular rash, erythrodermia, sicca, cholestasis | Steroids, CSA, MMF | Ongoing, 517 d+ | Thrombocytopenia | Negative 330 d+ | ||
| 52/F | B | None, unmut | 3 | GVHD grade II | 88 | Erythrodermia, sicca syndrome | Steroids | Resolved, 60 d | HHV6, cytopenia | Negative 214 d+ | ||
| Rash | ||||||||||||
| 42/M | B | 11q-, 13q-, unmut | 1 | — | 601 | Urticaria | None | Resolved, 294 d | HHV6, cytopenia, autoimmune thyroiditis | Negative 943 d+ | ||
| 50/M | B | 14q-, unmut | 3 | — | 52 | Maculopapular rash | Steroids | Resolved | HHV6, cytopenia, herpes zoster, Guillain-Barré syndrome | NA | ||
| 54/F | B | 11q-, unmut | 2 | — | 211 | Maculopapular rash | Steroids | Resolved | Pneumocystic carinii pneumonia; patient died | Negative 1 d+ | ||
| 55/M | B | 11q-, +12, unmut | 3 | Interface dermatitis | 116 | Erythema | Steroids | Ongoing, 327 d+ | Thrombocytopenia | Positive | ||
| 42/M | B | +12q, unmut | 3 | — | 102 | Maculopapular rash | Steroids | Resolved, 30 d | None | Negative 708 d | ||
| None | ||||||||||||
| 58/M* | B | 13q-, unmut | 0 | — | — | — | — | — | Lung cancer; patient died | Negative 157 d | ||
| 48/M | B | 11q-, unmut | 0 | — | — | — | — | — | CMV, VZV encephalitis, cytopenia, | Negative 157 d+ | ||
| 57/M | B | None, unmut | 0 | — | — | Weight loss, sicca syndrome | — | — | Pneumonia and ARDS; patient died | Positive | ||
| 65/M | B | 13q-, 17p-, unmut | 0 | — | — | — | — | — | CMV, cytopenia, sepsis; patient died | Negative 1 d+ | ||
Patient age, y/sex . | Binet stage . | Cytogenetics, VH status . | Stage, skin . | . | Onset, d . | GVHD/rash . | . | . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Histology . | . | Manifestation . | Treatment . | Outcome . | Complications and outcome . | MRD . | ||
| GVHD | ||||||||||||
| 64/M | B | 11q-, unmut | 3 | GVHD grade I | 92 | Maculopapular rash, conjunctivitis, sicca syndrome, wasting syndrome, diarrhea, duodenitis | Steroids, CSA, FK506 | Ongoing, 638 d+ | Cytopenia, pneumonia; patient died | Negative 439 d+ | ||
| 53/F | B | None, unmut | 1 | Acute GVHD | 43 | Maculopapular rash | Steroids, topical steroids | Ongoing, 867 d+ | CMV, herpes zoster | Negative 876 d+ | ||
| 51/F | B | None, unmut | 1 | GVHD grade I | 324 | Erythema, eczema, conjunctivitis, sicca syndrome, cholestasis | Steroids | Ongoing, 428 d+ | CLL transformation, allogeneic SCT | NA | ||
| 51/M | C | 13q-, unmut | 3 | — | 63 | Eczema, erythrodermia, conjunctivitis, sicca syndrome, cholestasis, diarrhea | Steroids | Resolved, 619 d | VZV, pneumonitis, Hashimoto thyroiditis | Negative 511 d+ | ||
| 34/M | C | None, unmut | 1 | — | 149 | Itching, dry and scalding skin, conjunctivitis, cholestasis | Topical steroids | Resolved, 399 d | Cytopenia, herpes zoster | Negative 511 d+ | ||
| 54/M | B | 13q-, mut | 3 | GVHD grade I | 68 | Maculopapular rash, erythrodermia, sicca, cholestasis | Steroids, CSA, MMF | Ongoing, 517 d+ | Thrombocytopenia | Negative 330 d+ | ||
| 52/F | B | None, unmut | 3 | GVHD grade II | 88 | Erythrodermia, sicca syndrome | Steroids | Resolved, 60 d | HHV6, cytopenia | Negative 214 d+ | ||
| Rash | ||||||||||||
| 42/M | B | 11q-, 13q-, unmut | 1 | — | 601 | Urticaria | None | Resolved, 294 d | HHV6, cytopenia, autoimmune thyroiditis | Negative 943 d+ | ||
| 50/M | B | 14q-, unmut | 3 | — | 52 | Maculopapular rash | Steroids | Resolved | HHV6, cytopenia, herpes zoster, Guillain-Barré syndrome | NA | ||
| 54/F | B | 11q-, unmut | 2 | — | 211 | Maculopapular rash | Steroids | Resolved | Pneumocystic carinii pneumonia; patient died | Negative 1 d+ | ||
| 55/M | B | 11q-, +12, unmut | 3 | Interface dermatitis | 116 | Erythema | Steroids | Ongoing, 327 d+ | Thrombocytopenia | Positive | ||
| 42/M | B | +12q, unmut | 3 | — | 102 | Maculopapular rash | Steroids | Resolved, 30 d | None | Negative 708 d | ||
| None | ||||||||||||
| 58/M* | B | 13q-, unmut | 0 | — | — | — | — | — | Lung cancer; patient died | Negative 157 d | ||
| 48/M | B | 11q-, unmut | 0 | — | — | — | — | — | CMV, VZV encephalitis, cytopenia, | Negative 157 d+ | ||
| 57/M | B | None, unmut | 0 | — | — | Weight loss, sicca syndrome | — | — | Pneumonia and ARDS; patient died | Positive | ||
| 65/M | B | 13q-, 17p-, unmut | 0 | — | — | — | — | — | CMV, cytopenia, sepsis; patient died | Negative 1 d+ | ||
Skin stage was graded according to Glucksberg criteria.11 Genetic characterization was performed as previously described.12,13
ARDS indicates acute respiratory distress syndrome; CMV, cytomegalovirus; FK506, tacrolimus; HHV6, human herpes virus 6; MMF, mycophenolate mofetil; mut, mutated VH; NA, not available; none, no aberrations detected by fluorescence in situ hybridization; unmut, unmutated VH; VZV, varicella-zoster virus; and-, not applicable.
Patient received a CD34-selected transplant.